191 results on '"Crary, Shelley E"'
Search Results
2. Mental health in persons with von Willebrand disease in the United States – a large national database study
3. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
4. Anticoagulation and vascular anomalies
5. Pupil Size and Reactivity in Pediatric Patients With Sickle Cell Disease
6. Vascular Anomalies
7. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
8. Multiple Autoimmune Disorders in Aicardi-Goutières Syndrome
9. Acquired Hemophilia: A Rare Complication of Pediatric Idiopathic Multicentric Castleman Disease.
10. Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study.
11. Vascular Anomalies
12. Barriers to Genetic Testing in Vascular Malformations
13. Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia
14. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
15. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
16. Autoimmune Lymphoproliferative Syndrome Masquerading as Posttransplant Lymphoproliferative Disorder
17. How we approach coagulopathy with vascular anomalies
18. Comparative Effectiveness of Different Types of Splenectomy for Children with Congenital Hemolytic Anemias
19. A case of bruising and joint hypermobility: The need to consider genetic testing for platelet disorders.
20. Pharmacokinetics of bleomycin sclerotherapy in patients with vascular malformations
21. Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia
22. Pupil Size and Reactivity in Pediatric Patients With Sickle Cell Disease
23. Vascular complications after splenectomy for hematologic disorders
24. Clinical outcomes of splenectomy in children: Report of the splenectomy in congenital hemolytic anemia registry
25. Surveillance Chest X-Ray and Pulmonary Function Testing in Patients Undergoing Intralesional Bleomycin in the Treatment of Vascular Malformations
26. Long‐term biological effects in sickle cell disease: insights from a post‐crizanlizumab study
27. Safety and Pharmacokinetics of Recombinant ADAMTS13 in Patients with Sickle Cell Disease: A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study
28. Poor School Performance As an Indicator of Severity of Sickle Cell Disease
29. A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
30. Iron Deficiency: When and Why Oral Iron May Not Be Enough
31. Prominent Forehead Hematomas (“Goose-Eggs”) as an Initial Manifestation of Hemophilia
32. Intravenous low molecular weight iron dextran in children with iron deficiency anemia unresponsive to oral iron
33. Venous thrombosis and thromboembolism in children with osteomyelitis
34. Hemolytic non-uremic syndrome
35. Prevalence of pulmonary hypertension in hereditary spherocytosis
36. Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy
37. Analyzing coagulation dynamics during treatment of vascular malformations with thromboelastography
38. Traditional laboratory measures of cardiovascular risk in hereditary spherocytosis†
39. Postsplenectomy vascular complications: Feasibility of studying patients with splenectomy following trauma
40. Laboratory Markers of Thrombosis Risk in Children With Hereditary Spherocytosis
41. Cancer Risk in Klippel–Trenaunay Syndrome
42. Effect of sirolimus on coagulopathy of slow-flow vascular malformations
43. Second‐line treatments in children with immune thrombocytopenia: Effect on platelet count and patient‐centered outcomes
44. Analyzing coagulation dynamics during treatment of vascular malformations with thromboelastography.
45. Effectiveness and Safety of Treatment with Direct Oral Anticoagulant Rivaroxaban in Patients with Slow-Flow Vascular Malformations: A Case Series
46. Physician decision making in selection of second-line treatments in immune thrombocytopenia in children
47. Short-term side effects and patient-reported outcomes of bleomycin sclerotherapy in vascular malformations
48. Physician Factors Determining Treatment Decisions in Selecting Second Line Agents for Pediatric ITP
49. Comparison of Bleeding Tools in a Cohort of Pediatric Patients with ITP: Data from the Pediatric ITP Consortium of North America ICON1 Study
50. Clinical Characteristics and Quality of Life of Children with ITP Starting Second Line Treatments: Data from the ITP Consortium of North America ICON1 Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.